Dova Pharmaceuticals Inc (NASDAQ:DOVA) – Equities researchers at Wedbush dropped their FY2022 earnings estimates for Dova Pharmaceuticals in a research report issued to clients and investors on Tuesday, August 6th. Wedbush analyst L. Chico now forecasts that the company will post earnings of $3.81 per share for the year, down from their previous estimate of $4.17. Wedbush has a “Outperform” rating and a $19.00 price objective on the stock.
DOVA has been the subject of a number of other research reports. JPMorgan Chase & Co. lifted their price target on shares of Dova Pharmaceuticals from $13.00 to $15.00 and gave the stock an “underweight” rating in a research note on Friday, July 12th. Evercore ISI upgraded shares of Dova Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $15.00 price target for the company in a research note on Monday, July 1st. HC Wainwright lifted their price target on shares of Dova Pharmaceuticals from $18.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. BidaskClub upgraded shares of Dova Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research lowered shares of Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 16th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Dova Pharmaceuticals has an average rating of “Buy” and an average target price of $27.13.
Dova Pharmaceuticals (NASDAQ:DOVA) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.03). The firm had revenue of $3.52 million for the quarter, compared to analysts’ expectations of $5.63 million. Dova Pharmaceuticals had a negative net margin of 521.67% and a negative return on equity of 87.20%.
Hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp raised its position in Dova Pharmaceuticals by 4.9% in the fourth quarter. Bank of New York Mellon Corp now owns 49,907 shares of the company’s stock worth $378,000 after acquiring an additional 2,313 shares in the last quarter. DekaBank Deutsche Girozentrale raised its position in Dova Pharmaceuticals by 22.0% in the first quarter. DekaBank Deutsche Girozentrale now owns 13,300 shares of the company’s stock worth $336,000 after acquiring an additional 2,400 shares in the last quarter. Birchview Capital LP raised its position in Dova Pharmaceuticals by 25.0% in the first quarter. Birchview Capital LP now owns 50,000 shares of the company’s stock worth $445,000 after acquiring an additional 10,000 shares in the last quarter. FMR LLC raised its position in Dova Pharmaceuticals by 0.8% in the first quarter. FMR LLC now owns 1,347,521 shares of the company’s stock worth $11,979,000 after acquiring an additional 10,970 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Dova Pharmaceuticals by 8.1% in the fourth quarter. Geode Capital Management LLC now owns 156,232 shares of the company’s stock worth $1,184,000 after acquiring an additional 11,732 shares in the last quarter. 31.18% of the stock is owned by institutional investors and hedge funds.
In related news, major shareholder Life Sciences Maste Perceptive acquired 427,209 shares of Dova Pharmaceuticals stock in a transaction that occurred on Friday, June 28th. The stock was acquired at an average price of $13.35 per share, with a total value of $5,703,240.15. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO David Zaccardelli sold 10,450 shares of the company’s stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $15.94, for a total transaction of $166,573.00. The disclosure for this sale can be found here. In the last ninety days, insiders purchased 582,854 shares of company stock valued at $8,243,825 and sold 27,807 shares valued at $422,464. Corporate insiders own 60.30% of the company’s stock.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.
Read More: Front-End Load
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.